Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial
Overview
- Phase
- Phase 2
- Intervention
- Chloral Hydrate
- Conditions
- Traumatic Brain Injury
- Sponsor
- University of Sao Paulo
- Locations
- 1
- Primary Endpoint
- Adverse Events
- Status
- Withdrawn
- Last Updated
- 12 years ago
Overview
Brief Summary
Thousands of children receive sedation for diagnostic and therapeutic interventions annually, and this number is expected to increase. Children are at higher risk for sedation-related complications than adults. In different scenarios, multiple drugs are used to achieve sedation, each one with particular adverse events that must be monitored and reported.
Children that need CT scans for traumatic brain injuries often need sedation, without needing and IV line for that. Chloral hydrate is an hypnotic agent used since 1832 with low incidence of adverse events; however, despite its worldwide use, it's being abandoned due to bitter taste, long time of sedation onset, vomiting and mild sedation. Intranasal midazolam, on the other hand, produces high and fast concentrations on CSF with greater rates of success but probably with higher adverse events. There are no prospective studies with large series of patients using intranasal midazolam.
The aim of this study is to determine if nasal midazolam is a safer approach and more effective sedative regimen when compared to rectal chloral hydrate to children undergoing CT scans.
Investigators
Eligibility Criteria
Inclusion Criteria
- •children undergoing CT scanning for TBI
Exclusion Criteria
- •epistaxis
- •suspected or confirmed skull or nasal fracture
- •Moderate to severe traumatic brain injury
- •hemodynamically unstable
Arms & Interventions
Chloral hydrate
Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
Intervention: Chloral Hydrate
Midazolam
Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
Intervention: Midazolam
Outcomes
Primary Outcomes
Adverse Events
Time Frame: Participants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hours
Such as hypoxemia, respiratory depression, vomiting, hypotension
Secondary Outcomes
- Efficacy of both drugs(Participants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hours)